The Efficacy and Safety of Enarodustat for the Treatment of Anemia in Hemodialysis Dependent Chronic Kidney Disease Patients: A Phase 3, Multicenter, Randomized, Active-Comparator (recombinant human erythropoietin), Open-Label Study：the ENARODIAL stu
Enarodustat was noninferior to rHuEPO for the treatment of anemia in HD-CKD patients , with good safety and tolerability over 24 weeks.
Authors
- Yuou Xia
- xiaonong chen
- Tianjun Guan (ORCID: https://orcid.org/0000-0001-9425-1641)
- Changyou Sun (ORCID: https://orcid.org/0000-0002-8784-6767)
- Yuanwen Xu (ORCID: https://orcid.org/0009-0005-8835-4050)
- Xiaojuan Lian
- Menghua Chen (ORCID: https://orcid.org/0000-0002-1298-2203)
- Ning Cao (ORCID: https://orcid.org/0000-0001-5114-028X)
- Ping Luo (ORCID: https://orcid.org/0009-0006-9471-3264)
- Yuehong Li (ORCID: https://orcid.org/0000-0002-4772-0641)
- Bicheng Liu
- Zibo Xiong
- Tiekun Yan
- Daqing Hong
- Zhihua Zheng
- Wei Chen
- Nan Mao
- Hua Zhou
- Zhen Ai
- Caili Wang
- Wenli Chen
- Qingping Chen
- Hong Cheng
- Qun Luo
- Zichen Liu
- Bin Zhu
- Yuehong Yan
- Song Wang
- Li Zhou
- Jianwen Wang
- Bo Liang
- Aicheng Yang
- Qiongqiong Yang
- Shengmei Mu
- Yongjun Shi
- Aiying Liu
- Hong Ye
- Yuanyuan Chen
- Haishan Wu
- Yu Wang
- Cheng Wang
- Yongjun Zhu
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1159/000550548
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00